X

News

August 2011: ReveraGen BioPharma Selected as Awardee for Inaugural National Institutes of Health’s Therapeutics for Rare and Neglected Diseases Program for its Novel Dissociative Glucocorticoid Analogue

Rockville, MD – ReveraGen BioPharma, Inc., a biopharmaceutical company developing alternatives to traditional steroid compounds, including dissociative glucocorticoid analogues for use in muscular dystrophy, has been selected by the National Institutes of Health’s (NIH) Therapeutics for Rare and Neglected Diseases (TRND) program, to partner on the development of a new treatment of Duchenne muscular dystrophy (DMD).